Patrick Duxbury and Robert Breedon lead the practice at Gowling WLG, which is noted for its ‘deep experience’ in licensing matters and pharmaceutical manufacturing issues. The team regularly assists large pharmaceutical companies such as BioNTech and AstraZeneca, and is known for representing care home and senior facility operators and funders. With his academic background in microbiology and genetics, Duxbury handles an array of transactional issues, including commercialisation deals and collaborations, while Breedon advises both public and private sector clients in the healthcare space on outsourcing contracts and commercial projects.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Small team with deep experience in life sciences licensing and collaboration deals.’
Key clients
- BioNTech
- Gyrus Captial
- Neurim Pharmaceuticals
- European Pharmaceutical Company
- AstraZeneca
- Eisai
- Bial Portela
- Katholike Universiteit Leuven
- Dynavax
- Argenx NV
- BioInvent International AB
- GlaxoSmithKline
- Apposite Capital
- Sosei Heptares
- Amphista Therapeutics
- Birmingham Women's and Children's Hospitals NHS Foundation Trust
- UDG Healthcare Group plc
- Circle Health
- Department of Health and Social Care
- Ford
- Formation Capital, LLC
- Fresenius Medical Care Renal Services Limited
- Getinge Group
- Guy's & St Thomas' NHS Foundation Trust
- Synlab Group
- Lakeside Healthcare
- Montreux Healthcare Fixed Yield Fund
- TT Electronics
- Oxford University Hospitals NHS Foundation Trust
- Sitekit Applications Limited
- NHS Birmingham and Solihull Mental Health NHS Foundation Trust
- Nucleic Acid Imaging Company
- UK Clinical Phase Biotech Company
- Oxford BioTherapeutics
- Immedica Pharma AB
- Sentinel Oncology
Work highlights
- Advised AstraZeneca on a strategic collaboration with diagnostic company, GRAIL, to develop and commercialise companion diagnostic assays for use with AstraZeneca’s therapies.
- Advised BioNTech on its collaboration with the UK Government to accelerate personalised mRNA immunotherapy clinic trails providing personalised cancer therapies for up to 10000 patients by 2030.
- Advised GSK on patent litigation proceedings brought by Pfizer in relation to RSV vaccines.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
The lawyer(s) leading their teams.
Patrick Duxbury, Robert Breedon